A new computational method reveals a faster way to explore intricate quantum systems, pointing toward emerging applications in next-generation computing. Credit: Stock A new quantum-inspired algorithm ...

Lets geek out. The HackerNoon library is now ranked by reading time created. Start learning by what others read most. Lets geek out. The HackerNoon library is now ranked by reading time created. Start ...

Abstract: In the last decade, 1-bit synthetic aperture radar (SAR) imaging has been proposed, which uses 1-bit quantized echo data for scene reconstruction, offering substantial reductions in system ...

Want to start a career in AI? Explore the top AI jobs in India for 2026, including ML Engineer salaries, required skills like ...

Bitcoin (BTC) has gone up 4.5% over the past week as renewed institutional demand helped stabilize prices. At the same time, derivatives data indicate a cooling in forced selling activity. Notably, ...

U.S. jobs data and eurozone provisional inflation figures for March will attract attention in the coming week as data begins to give a picture of how the war in the Middle East, and particularly the ...

Provisional purchasing managers’ surveys for March in the U.S. and Europe in the week will provide a key gauge of how the ongoing war in the Middle East has impacted sentiment and business activity.

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

A clump of human brain cells can play the classic computer game Doom. While its performance is not up to par with humans, experts say it brings biological computers a step closer to useful real-world ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...